News

Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage…

2 years ago

Neuronetics Announces Continued Momentum for Expanded Health Insurance Coverage for TMS Therapy

BlueCross BlueShield of Mississippi Latest to Allow Non-Physician Practitioners to Prescribe TMSMALVERN, Pa., April 13, 2023 (GLOBE NEWSWIRE) -- Neuronetics,…

2 years ago

Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer Mechanism

OncoBay Clinical is a boutique clinical research organization (CRO) that is a subsidiary of the Moffitt Cancer Center and has…

2 years ago

SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark

JERSEY CITY, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to…

2 years ago

Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering…

2 years ago

Galecto to Present Two Posters at AACR Annual Meeting 2023

BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin…

2 years ago

Surgalign Announces Receipt of Nasdaq Deficiency Notice and Intends to Submit Plan to Regain Compliance

DEERFIELD, Ill., April 13, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on…

2 years ago

SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza

FDA greenlights advancement of SAB-176 Phase 2b trial and manufacturing approach to address influenza strain change SAB-176 is the first…

2 years ago

Cerevance Announces Poster Presentation at the BNA International Festival of Neuroscience

BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous…

2 years ago

Ascendis Pharma Announces First Quarter 2023 Financial Results and Business Update Conference Call on April 27

COPENHAGEN, Denmark, April 13, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the company will hold…

2 years ago